Background The promise of precision cancer medicine presently centers around the
genomic sequence of a patient's tumor being translated into timely, actionable information to …

Precision medicine is now pivotal to design patients' specific treatment strategies with the
aim of prolonging progression and overall survival. In this regard, invasive tumor tissue …

Cell-free DNA fragments are shed into the bloodstream by tumor cells. The analysis of
circulating tumor DNA (ctDNA), commonly known as liquid biopsy, can be exploited for a …

Simple Summary An important advance in the diagnostic and surveillance toolbox for
oncologists is circulating tumor DNA (ctDNA). This technology can detect microscopic levels …

Improvements in genomic and molecular methods are expanding the range of potential
applications for circulating tumour DNA (ctDNA), both in a research setting and as a'liquid …

Techniques for analyzing circulating tumor DNA (ctDNA) to detect, characterize and monitor
cancer have matured rapidly. An increasing body of clinical evidence is demonstrating the …

BACKGROUND Targeted therapies have markedly changed the treatment of cancer over
the past 10 years. However, almost all tumors acquire resistance to systemic treatment as a …

The use of circulating tumor DNA (ctDNA) as a novel and non-invasive test for the diagnosis
and surveillance of cancer is a rapidly growing area of interest, with sequencing of ctDNA …

The pursuit of highly sensitive and specific cancer diagnostics based on cell‐free nucleic
acids isolated from minimally invasive liquid biopsies has been an area of intense research …

Circulating tumor DNA (ctDNA) in fluids has gained attention because ctDNA seems to
identify tumor-specific abnormalities, which could be used for diagnosis, follow-up of …